{"id":"standard-triple-therapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The combination of antibiotics and acid suppressors in this triple therapy works synergistically to effectively eliminate Helicobacter pylori bacteria from the stomach, reducing the risk of complications such as gastric ulcers and cancer.","oneSentence":"This triple therapy combines medications to treat Helicobacter pylori infections by inhibiting bacterial growth and promoting eradication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:26.225Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of Helicobacter pylori infections in adults"},{"name":"Eradication of H. pylori in patients with peptic ulcer disease"}]},"trialDetails":[{"nctId":"NCT03546686","phase":"PHASE2","title":"Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-11-12","conditions":"Breast Cancer","enrollment":51},{"nctId":"NCT02954874","phase":"PHASE3","title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-18","conditions":"Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7","enrollment":1155},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":"Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer","enrollment":50},{"nctId":"NCT07486687","phase":"PHASE3","title":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2026-04","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer","enrollment":1000},{"nctId":"NCT07486089","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)","enrollment":60},{"nctId":"NCT07340541","phase":"PHASE2","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-02","conditions":"Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer","enrollment":700},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT07239739","phase":"NA","title":"Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment","status":"NOT_YET_RECRUITING","sponsor":"Faiz ur rahman","startDate":"2026-06-15","conditions":"Periapical Lesion, Periapical Periodontitis","enrollment":62},{"nctId":"NCT06833853","phase":"","title":"A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients","status":"RECRUITING","sponsor":"Menarini Silicon Biosystems, INC","startDate":"2026-03-13","conditions":"Metastatic Breast Cancer (MBC)","enrollment":187},{"nctId":"NCT07428642","phase":"","title":"PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.","status":"COMPLETED","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-09-01","conditions":"Metastatic Hormone-Sensitive Prostate Cancer, Prostate Cancer","enrollment":168},{"nctId":"NCT05422794","phase":"PHASE1","title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-18","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma","enrollment":57},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT05639556","phase":"","title":"Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2023-04-20","conditions":"Cystic Fibrosis","enrollment":300},{"nctId":"NCT06134375","phase":"PHASE1, PHASE2","title":"A Study of Tetrathiomolybdate (TM) Plus Capecitabine","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2024-11-26","conditions":"Triple Negative Breast Cancer, Residual Disease","enrollment":204},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT07436988","phase":"PHASE1","title":"Affordable Made-in-India Microspheres for Liver Cancer Therapy","status":"NOT_YET_RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-02-15","conditions":"Hepatecellular Carcinoma","enrollment":18},{"nctId":"NCT05665348","phase":"PHASE2, PHASE3","title":"Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2023-03-09","conditions":"HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor","enrollment":229},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06710197","phase":"PHASE2","title":"IL-1 Inhibition in Early TNBC","status":"WITHDRAWN","sponsor":"University Health Network, Toronto","startDate":"2025-03-05","conditions":"Early Stage Triple Negative ER Low Breast Cancer","enrollment":""},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT07439211","phase":"PHASE1","title":"Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2026-07","conditions":"Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT07435961","phase":"NA","title":"Magnetotherapy in Carpal Tunnel Syndrome: Randomized Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Fatih Sultan Mehmet Training and Research Hospital","startDate":"2026-02-01","conditions":"Magnetotherapy, Carpal Tunnel Syndrome (CTS), Median Nerve Compression","enrollment":60},{"nctId":"NCT03808337","phase":"PHASE2","title":"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-01-16","conditions":"Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer","enrollment":145},{"nctId":"NCT05650723","phase":"PHASE2","title":"Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-08","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":50},{"nctId":"NCT07425808","phase":"PHASE2, PHASE3","title":"FLT3-ITD Targeted Therapy in Fit AML Patients","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2026-12-01","conditions":"AML (Acute Myeloid Leukemia)","enrollment":230},{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Triple Negative Breast Cancer","enrollment":85},{"nctId":"NCT05977309","phase":"NA","title":"Effect of Topical Ozone on The Healing Diabetic Foot Ulcer","status":"COMPLETED","sponsor":"Asmat Burhan","startDate":"2023-08-01","conditions":"Wound Heal, Diabetic Foot Ulcer, Ozone","enrollment":430},{"nctId":"NCT07407920","phase":"PHASE2","title":"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma","enrollment":120},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT07401537","phase":"PHASE2","title":"Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-12-31","conditions":"Triple -Negative Breast Cancer, Breast Cancer","enrollment":416},{"nctId":"NCT04966520","phase":"NA","title":"Accelerated Neuromodulation to Alleviate Cognitive Deficits Due to Cancer Therapy","status":"COMPLETED","sponsor":"Sneha Phadke","startDate":"2021-06-01","conditions":"Cancer","enrollment":15},{"nctId":"NCT07233928","phase":"NA","title":"Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2026-02-06","conditions":"Early Breast Cancer, Metastatic Breast Cancer","enrollment":1050},{"nctId":"NCT05528133","phase":"PHASE2","title":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-01-25","conditions":"Triple Negative Breast Cancer","enrollment":86},{"nctId":"NCT02962791","phase":"NA","title":"Prospective Randomized Trial Comparing TRIPLE Site ventriculAr Stimulation Versus Conventional Pacing in CRT canDidates","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2017-10-24","conditions":"Cardiac Resynchronization Therapy","enrollment":36},{"nctId":"NCT02876302","phase":"PHASE2","title":"Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-01-24","conditions":"Inflammatory Breast Cancer (IBC)","enrollment":23},{"nctId":"NCT07378306","phase":"PHASE2","title":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":80},{"nctId":"NCT06199232","phase":"NA","title":"Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University","startDate":"2024-01-23","conditions":"Liver Metastasis Colon Cancer, ctDNA Genotype, MSS","enrollment":47},{"nctId":"NCT07344779","phase":"","title":"A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-02-17","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1600},{"nctId":"NCT05909332","phase":"PHASE3","title":"Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-20","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":764},{"nctId":"NCT06349486","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2023-11-28","conditions":"Helicobacter Pylori Eradication","enrollment":390},{"nctId":"NCT07341867","phase":"PHASE1","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Andrew Hantel, MD","startDate":"2026-06","conditions":"Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation","enrollment":90},{"nctId":"NCT07311083","phase":"NA","title":"Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Kliniken Essen-Mitte","startDate":"2026-02-01","conditions":"Microbiome","enrollment":60},{"nctId":"NCT07334535","phase":"PHASE4","title":"Isa-VRD in TIE HRMM","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-30","conditions":"Multiple Myeloma","enrollment":117},{"nctId":"NCT06351332","phase":"PHASE1, PHASE2","title":"ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Filipa Lynce, MD","startDate":"2024-05-01","conditions":"Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer","enrollment":78},{"nctId":"NCT04870515","phase":"NA","title":"Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-11-04","conditions":"Localized Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":20},{"nctId":"NCT06588205","phase":"","title":"Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2025-05-05","conditions":"Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":200},{"nctId":"NCT07292142","phase":"PHASE1, PHASE2","title":"FMT in Triple Negative Breast Cancer Guided by ctDNA","status":"NOT_YET_RECRUITING","sponsor":"Jewish General Hospital","startDate":"2026-02","conditions":"Breast Cancer","enrollment":125},{"nctId":"NCT07290153","phase":"","title":"Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-01","conditions":"Breast Cancer Female NOS, General Anxiety Disorder, Depressive Disorder","enrollment":120},{"nctId":"NCT04722978","phase":"PHASE3","title":"Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2021-04-20","conditions":"Triple Negative Breast Cancer","enrollment":228},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT07104318","phase":"PHASE3","title":"Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Helicobacter Pylori","enrollment":360},{"nctId":"NCT06152705","phase":"NA","title":"Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression","status":"RECRUITING","sponsor":"The Royal Ottawa Mental Health Centre","startDate":"2024-09-16","conditions":"Depression, Depressive Disorder, Major, Depressive Episode","enrollment":210},{"nctId":"NCT06492759","phase":"PHASE2","title":"High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-01-31","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":29},{"nctId":"NCT02323581","phase":"NA","title":"Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts","status":"RECRUITING","sponsor":"Darren Schneider, M.D.","startDate":"2013-11","conditions":"Aortic Aneurysm, Thoracoabdominal, Aortic Aneurysm, Thoracic, Aortic Dissection, Thoracoabdominal","enrollment":520},{"nctId":"NCT07278115","phase":"NA","title":"Effects on Remission of Type 2 Diabetes Mellitus Following Gastric Bypass Alone vs Gastric Bypass Combined With Truncal Vagotomy","status":"NOT_YET_RECRUITING","sponsor":"University Research Institute for the Study of Genetic & Malignant Disorders in Childhood","startDate":"2025-12","conditions":"Diabetes Mellitus Type 2","enrollment":40},{"nctId":"NCT03483012","phase":"PHASE2","title":"Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-05-01","conditions":"Breast Cancer","enrollment":6},{"nctId":"NCT05564650","phase":"PHASE1","title":"Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-01-12","conditions":"Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome","enrollment":6},{"nctId":"NCT06664801","phase":"PHASE2","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-11-14","conditions":"Pulmonary Arterial Hypertension","enrollment":164},{"nctId":"NCT06925750","phase":"PHASE2","title":"A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-12","conditions":"Pulmonary Arterial Hypertension","enrollment":130},{"nctId":"NCT05623397","phase":"","title":"A Deep Learning Method to Evaluate QT on Ribociclib","status":"COMPLETED","sponsor":"CMC Ambroise Paré","startDate":"2023-07-28","conditions":"Breast Cancer, Ribociclib","enrollment":70},{"nctId":"NCT02688803","phase":"PHASE4","title":"Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-08-30","conditions":"Breast Cancer","enrollment":2},{"nctId":"NCT07259733","phase":"NA","title":"Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","status":"RECRUITING","sponsor":"Instituto Dante Pazzanese de Cardiologia","startDate":"2023-07-15","conditions":"Apparent Resistant Hypertension, Hypertension, High Blood Pressure","enrollment":142},{"nctId":"NCT05180006","phase":"PHASE2","title":"Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2022-02-24","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT05383170","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers","status":"COMPLETED","sponsor":"Cytovation AS","startDate":"2023-03-21","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma","enrollment":6},{"nctId":"NCT07246681","phase":"PHASE3","title":"Lignin in Treatment of Helicobacter Pylori Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2025-10-31","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":70},{"nctId":"NCT05088395","phase":"NA","title":"Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2022-05-19","conditions":"Cancer","enrollment":2050},{"nctId":"NCT06078384","phase":"PHASE2","title":"Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-12-27","conditions":"Triple-negative Breast Cancer","enrollment":354},{"nctId":"NCT05973864","phase":"PHASE2","title":"Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-03-11","conditions":"Triple Negative Breast Neoplasms","enrollment":220},{"nctId":"NCT03979508","phase":"PHASE2","title":"Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2020-01-10","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":26},{"nctId":"NCT02593175","phase":"PHASE2","title":"Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-03","conditions":"Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7","enrollment":43},{"nctId":"NCT07059975","phase":"EARLY_PHASE1","title":"UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML","status":"RECRUITING","sponsor":"Joanna Yi","startDate":"2025-10-22","conditions":"Acute Myeloid Leukemia, Pediatric AML","enrollment":36},{"nctId":"NCT06683092","phase":"","title":"Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2025-05-01","conditions":"Cystic Fibrosis","enrollment":200},{"nctId":"NCT07016399","phase":"PHASE2","title":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","status":"RECRUITING","sponsor":"Vandana Abramson","startDate":"2025-09-09","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma","enrollment":51},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT06060587","phase":"PHASE2","title":"Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2023-10-19","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT02711137","phase":"PHASE1, PHASE2","title":"Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2016-05-18","conditions":"Solid Tumors","enrollment":137},{"nctId":"NCT02744053","phase":"EARLY_PHASE1","title":"DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-11-07","conditions":"Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative","enrollment":96},{"nctId":"NCT04997109","phase":"NA","title":"Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-02-23","conditions":"Cerebral Palsy","enrollment":267},{"nctId":"NCT04230109","phase":"PHASE2","title":"Sacituzumab Govitecan In TNBC","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-14","conditions":"Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer","enrollment":260},{"nctId":"NCT06789757","phase":"PHASE2","title":"The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2025-02-25","conditions":"Hepatocellular Carcinoma","enrollment":19},{"nctId":"NCT04405167","phase":"PHASE1","title":"Tasquinimod for the Treatment of Relapsed or Refractory Myeloma","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT04501614","phase":"PHASE1, PHASE2","title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2021-02-24","conditions":"Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)","enrollment":11},{"nctId":"NCT05510895","phase":"PHASE2","title":"Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2022-09-01","conditions":"Colorectal Cancer, Colon Cancer, BRAF V600E","enrollment":2},{"nctId":"NCT02826434","phase":"PHASE1","title":"Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2016-08-18","conditions":"Breast Cancer","enrollment":22},{"nctId":"NCT07063095","phase":"PHASE3","title":"A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections","status":"RECRUITING","sponsor":"Angela HUTTNER","startDate":"2025-08-25","conditions":"Gram Negative Infections, Sepsis and Septic Shock","enrollment":100},{"nctId":"NCT07182331","phase":"NA","title":"Brain Stimulation and Sensory Integration in Children With ASD","status":"ENROLLING_BY_INVITATION","sponsor":"Neurolab Plus","startDate":"2025-08-25","conditions":"Autism Spectrum Disorder (ASD)","enrollment":40},{"nctId":"NCT07181395","phase":"NA","title":"Mulligan Mobilization Techniques for Non-Specific Low Back Pain","status":"NOT_YET_RECRUITING","sponsor":"Gazi University","startDate":"2025-09-07","conditions":"Non-specific Low Back Pain (NSLBP)","enrollment":30},{"nctId":"NCT07178730","phase":"PHASE3","title":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"West German Study Group","startDate":"2026-01-31","conditions":"Breast Cancer, Triple-negative Breast Cancer","enrollment":765},{"nctId":"NCT06938724","phase":"PHASE2","title":"Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2025-07-25","conditions":"Breast Neoplasm Malignant Female","enrollment":152},{"nctId":"NCT07161791","phase":"PHASE1, PHASE2","title":"Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2025-09-15","conditions":"Breast Cancer, Triple Negative Breast Cancer (TNBC)","enrollment":12},{"nctId":"NCT05610163","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-12-08","conditions":"Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":783},{"nctId":"NCT07031388","phase":"NA","title":"Mouthwashes for Gingivitis: Comparing a Hydrogen Peroxide-Hyaluronic Acid Mix, Hyaluronic Acid, and Chlorhexidine, A Triple-Blind Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ramziyah Hayder Bakr","startDate":"2025-07-01","conditions":"Plaque Induced Gingival Disease","enrollment":80},{"nctId":"NCT06505018","phase":"NA","title":"Telemonitoring Platform \"CUREETY TECHCARE\" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-25","conditions":"Metastatic Triple-Negative Breast Carcinoma","enrollment":472},{"nctId":"NCT04299893","phase":"PHASE2, PHASE3","title":"Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)","status":"RECRUITING","sponsor":"Bernardino Clavo, MD, PhD","startDate":"2020-11-30","conditions":"Chemotherapy-induced Peripheral Neuropathy, Pain, Neuropathic, Pain Syndrome","enrollment":42},{"nctId":"NCT03977467","phase":"PHASE2","title":"Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2019-08-30","conditions":"Non-Small Cell Lung Cancer, Solid Tumor","enrollment":46},{"nctId":"NCT07143097","phase":"PHASE2","title":"Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2021-11-01","conditions":"Triple -Negative Breast Cancer","enrollment":80},{"nctId":"NCT07075146","phase":"PHASE3","title":"DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-05-05","conditions":"HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity","enrollment":306}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Klaricid, Rabiet, Pamoxin","Amoxicillin 1000 mg orally twice daily","Omeprazole 20 mg orally twice daily","Clarithromycin 500 mg orally twice daily","7-day PPI-based standard triple therapy"],"phase":"phase_3","status":"active","brandName":"Standard triple therapy","genericName":"Standard triple therapy","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Standard triple therapy involves the use of cisplatin injection and gemcitabine, and capecitabine tablets, which are administered to treat various conditions including breast cancer and chronic hepatitis C. The mechanism of action of this therapy is through small molecule modality, although the specific mechanism is not detailed in the provided information.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}